Clinical and pathological analysis of C3 glomerulonephritis in 6 children
Abstract:Objective To analyze the clinical characteristics,pathological features and treatment responses of 6 pediatric patients with C3 glomerulonephritis (C3GN),in order to improve the understanding and treatment of this disease for pediatricians.Methods Analyze the clinical manifestations,pathological features,therapies,prognosis of patients who were diagnosed with C3 glomerulonephritis from September,2010 to June,2016 retrospectively.Results Clinical characteristics and laboratory examination:2 patients' first symptom was hematuria;4 patients'first symptom was hematuria and proteinuria;3 patients presented as acute nephritic syndrome,one presented as nephrotic syndrome.All the patients showed that the level of serum complement C3 was reduced,while sernm complement C4 was normal.Pathological character:6 patients showed strong positive complement C3 deposition under immunofluorescence.Lightmicroscopy showed mesangial proliferative glomerulonephritis in 5 cases,1 case was diagnosed as endocapillary proliferative glomerulonephritisin,and 3 patients presented electrondense depositionin under electron microscope.Treatment and prognosis:after conventional treatment,2 patients who were with crescent were treated with glucocorticoid.After a follow-up from 6 months to 42 months,the prognosis was pretty good.Conclusion Children with C3GN are usually presented with hematuria and (or)proteinuria,characterized by strong positive C3 deposition.Lightmicroscopy always shows mesangial proliferative glomerulonephritis.Electron microscope show electron dense deposition,and short-term prognosis is pretty good.
Keywords:childC3 glomerulonephritisrenal pathologytreatment and follow-up
Publication Date:2017-01-01
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:5( 374-378 )
Chinese Journal of Practical Pediatrics

Chinese Journal of Practical Pediatrics

PKUISTIC
ISSN:1005-2224
Year, Vol.(Issue):2017,32(5)